{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:13:19Z","timestamp":1747195999013,"version":"3.40.5"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Oncogenic fusions represent compelling druggable targets in solid tumours highlighted by the recent site agnostic FDA approval of larotrectinib for NTRK rearrangements. However screening for fusions in routinely processed tissue samples is constrained due to degradation of nucleic acid as a result of formalin fixation., To investigate the clinical utility of semiconductor sequencing optimised for detection of actionable fusion transcripts in formalin fixed samples, we have undertaken an analysis of test trending data generated by a clinically validated next generation sequencing platform designed to capture 867 of the most clinically relevant druggable driver-partner oncogenic fusions. Here we show across a real-life cohort of 1112 patients with solid tumours that actionable fusions occur at high frequency (7.4%) with linkage to a wide range of targeted therapy protocols including seven fusion-drug matches with FDA\/EMA approval and\/or NCCN\/ESMO recommendations and 80 clinical trials. The more prevalent actionable fusions identified were independent of tumour type in keeping with signalling via evolutionary conserved RAS\/RAF\/MEK\/ERK, PI3K\/AKT\/MTOR, PLCy\/PKC and JAK\/STAT pathways. Taken together our data indicates that semiconductor sequencing for detection of actionable fusions can be integrated into routine diagnostic pathology workflows enabling the identification of personalised treatment options that have potential to improve clinical cancer management across many tumour types.<\/jats:p>","DOI":"10.1371\/journal.pone.0246778","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T17:41:56Z","timestamp":1660930916000},"page":"e0246778","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-6528","authenticated-orcid":true,"given":"Marco","family":"Loddo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keeda-Marie","family":"Hardisty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2177-1421","authenticated-orcid":true,"given":"Alexander","family":"Llewelyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Haddow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"pone.0246778.ref001","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"N Stransky","year":"2014","journal-title":"Nat Commun"},{"issue":"14","key":"pone.0246778.ref002","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0246778.ref003","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer","volume":"13","author":"R Ferrara","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"10","key":"pone.0246778.ref004","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","article-title":"The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics","volume":"11","author":"TY Cheng","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"7","key":"pone.0246778.ref005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.21037\/atm.2019.03.36","article-title":"A paradigm shift in biomarker guided oncology drug development","volume":"7","author":"JT J\u00f8rgensen","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"pone.0246778.ref006","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First Global Approval","volume":"79","author":"LJ Scott","year":"2019","journal-title":"Drugs"},{"issue":"15","key":"pone.0246778.ref007","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA Approval Agnostic of Cancer Site\u2014When a Biomarker Defines the Indication","volume":"377","author":"S Lemery","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0246778.ref008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"MM Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"9","key":"pone.0246778.ref009","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"J Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"pone.0246778.ref010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/jcm7060144","article-title":"Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?","volume":"7","author":"S Garinet","year":"2018","journal-title":"J Clin Med"},{"issue":"21","key":"pone.0246778.ref011","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.18632\/oncotarget.26777","article-title":"Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors","volume":"10","author":"M Tuna","year":"2019","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0246778.ref012","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","article-title":"Driver Fusions and Their Implications in the Development and Treatment of Human Cancers","volume":"23","author":"Q Gao","year":"2018","journal-title":"Cell Rep"},{"issue":"9","key":"pone.0246778.ref013","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/14737159.2016.1220835","article-title":"Fusion genes in solid tumors: the possibilities and the pitfalls","volume":"16","author":"FG Barr","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"issue":"10","key":"pone.0246778.ref014","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1093\/nar\/gkw282","article-title":"Discovering and understanding oncogenic gene fusions through data intensive computational approaches","volume":"44","author":"NS Latysheva","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"pone.0246778.ref015","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/annonc\/mdy054","article-title":"Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project","volume":"29","author":"C. Turnbull","year":"2018","journal-title":"Ann Oncol"},{"issue":"15","key":"pone.0246778.ref016","doi-asserted-by":"crossref","first-page":"12316","DOI":"10.18632\/oncotarget.24384","article-title":"Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs","volume":"9","author":"DS Haslem","year":"2018","journal-title":"Oncotarget"},{"issue":"32","key":"pone.0246778.ref017","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials","volume":"33","author":"M Schwaederle","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15","key":"pone.0246778.ref018","doi-asserted-by":"crossref","first-page":"suppl.e13642","DOI":"10.1200\/JCO.2020.38.15_suppl.e13642","article-title":"The actionable genomic mutational landscape in solid tumours","volume":"38","author":"M Loddo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0246778.ref019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00428-016-2025-7","article-title":"Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL","volume":"470","author":"IQN Path ASBL","year":"2017","journal-title":"Virchows Arch"},{"issue":"D1","key":"pone.0246778.ref020","doi-asserted-by":"crossref","first-page":"D1144","DOI":"10.1093\/nar\/gkx1018","article-title":"Tumor Fusions: an integrative resource for cancer-associated transcript fusions","volume":"46","author":"X Hu","year":"2018","journal-title":"Nucleic Acids Research"},{"key":"pone.0246778.ref021","unstructured":"Gaines ME. Charting a Course: Navigating the Hype and the Hope of Precision Medicine Together. ASCO Guest commentary. https:\/\/connection.asco.org\/blogs\/charting-course-navigating-hype-and-hope-precision-medicine-together. Deposited 5 August, 2019."},{"issue":"8","key":"pone.0246778.ref022","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology","volume":"4","author":"J Marquart","year":"2018","journal-title":"JAMA Oncol"},{"key":"pone.0246778.ref023","first-page":"2017","article-title":"Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study","author":"AM Tsimberidou","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"21","key":"pone.0246778.ref024","doi-asserted-by":"crossref","first-page":"15792","DOI":"10.18632\/oncotarget.24353","article-title":"Value-based genomics","volume":"9","author":"J Gong","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0246778.ref025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"K Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"pone.0246778.ref026","doi-asserted-by":"crossref","first-page":"9303","DOI":"10.2147\/OTT.S218796","article-title":"FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib","volume":"12","author":"X Ying","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"11","key":"pone.0246778.ref027","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1101\/gr.165126.113","article-title":"RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas","volume":"24","author":"ZS Bao","year":"2014","journal-title":"Genome Res"},{"issue":"7413","key":"pone.0246778.ref028","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature11282","article-title":"Recurrent R-spondin fusions in colon cancer","volume":"488","author":"S Seshagiri","year":"2012","journal-title":"Nature"},{"issue":"7","key":"pone.0246778.ref029","doi-asserted-by":"crossref","first-page":"e27707","DOI":"10.1002\/pbc.27707","article-title":"AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma","volume":"66","author":"L Sisdelli","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"pone.0246778.ref030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/cas.13129","article-title":"Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities","volume":"108","author":"M Ibata","year":"2017","journal-title":"Cancer Sci"},{"issue":"17","key":"pone.0246778.ref031","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.7150\/jca.26256","article-title":"NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines","volume":"9","author":"SY Kim","year":"2018","journal-title":"J Cancer"},{"key":"pone.0246778.ref032","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1038\/srep09755","article-title":"Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers","volume":"5","author":"JS Jang","year":"2015","journal-title":"Sci Rep"},{"issue":"23","key":"pone.0246778.ref033","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/onc.2016.486","article-title":"Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK\/PI3K inhibition or MEK\/CDK4\/6 inhibition","volume":"36","author":"HS Kim","year":"2017","journal-title":"Oncogene"},{"key":"pone.0246778.ref034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cancergen.2017.03.001","article-title":"A novel cytogenetic and molecular characterization of renal metanephric adenoma: Identification of partner genes involved in translocation t(9;15)(p24;q24)","volume":"214\u2013215","author":"A Catic","year":"2017","journal-title":"Cancer Genet"},{"key":"pone.0246778.ref035","first-page":"159","volume-title":"The biology of cancer","author":"RA Weinberg","year":"2007","edition":"15"},{"issue":"3","key":"pone.0246778.ref036","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ncb2689","article-title":"A genomic toolkit to investigate kinesin and myosin motor function in cells","volume":"15","author":"Z Maliga","year":"2013","journal-title":"Nat Cell Biol"},{"key":"pone.0246778.ref037","unstructured":"RET proto-oncogene. Tissue atlas. The human protein atlas. https:\/\/www.proteinatlas.org\/ENSG00000165731-RET\/tissue"},{"issue":"16","key":"pone.0246778.ref038","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1038\/sj.onc.1209268","article-title":"Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET\/PTC rearrangements","volume":"25","author":"M Gandhi","year":"2006","journal-title":"Oncogene"},{"issue":"5489","key":"pone.0246778.ref039","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1126\/science.290.5489.138","article-title":"Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells","volume":"290","author":"MN Nikiforova","year":"2000","journal-title":"Science"},{"issue":"4","key":"pone.0246778.ref040","doi-asserted-by":"crossref","first-page":"eaaw6938","DOI":"10.1126\/sciadv.aaw6938","article-title":"Single-cell morphology encodes metastatic potential","volume":"6","author":"PH Wu","year":"2020","journal-title":"Sci Adv"},{"issue":"17","key":"pone.0246778.ref041","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.febslet.2014.06.027","article-title":"Targeting Alp7\/TACC to the spindle pole body is essential for mitotic spindle assembly in fission yeast","volume":"588","author":"NH Tang","year":"2014","journal-title":"FEBS Lett"},{"issue":"42","key":"pone.0246778.ref042","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1038\/sj.onc.1210446","article-title":"Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage","volume":"26","author":"F Merolla","year":"2007","journal-title":"Oncogene"},{"issue":"8","key":"pone.0246778.ref043","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1158\/0008-5472.CAN-11-2562","article-title":"INT6\/EIF3E interacts with ATM and is required for proper execution of the DNA damage response in human cells","volume":"72","author":"C Morris","year":"2012","journal-title":"Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T17:42:36Z","timestamp":1660930956000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246778"}},"subtitle":[],"editor":[{"given":"Honey V.","family":"Reddi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246778","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,8,19]]}}}